MEIP
Income statement / Annual
Last year (2025), MEI Pharma, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, MEI Pharma, Inc.'s net income was -$15.95 M.
See MEI Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00 |
$65.30 M |
$48.82 M |
$40.70 M |
$25.54 M |
$28.91 M |
$4.92 M |
$1.62 M |
$23.25 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$383.00 K
|
$1.82 M
|
$0.00
|
$1.41 M
|
$2.67 M
|
$4.26 M
|
$3.38 M
|
$5.00 M
|
$58.00 K
|
| Gross Profit |
$0.00
|
$64.91 M
|
$47.00 M
|
$40.70 M
|
$24.13 M
|
$26.24 M
|
$652.00 K
|
-$1.76 M
|
$18.25 M
|
-$58.00 K
|
| Gross Profit Ratio |
0
|
0.99
|
0.96
|
1
|
0.94
|
0.91
|
0.13
|
-1.09
|
0.78
|
0
|
| Research and Development Expenses |
$3.92 M
|
$16.56 M
|
$52.45 M
|
$85.64 M
|
$69.40 M
|
$34.07 M
|
$32.30 M
|
$17.04 M
|
$7.24 M
|
$13.40 M
|
| General & Administrative Expenses |
$13.53 M
|
$23.30 M
|
$33.13 M
|
$30.54 M
|
$24.41 M
|
$16.72 M
|
$14.60 M
|
$9.79 M
|
$8.63 M
|
$5.67 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.53 M
|
$23.30 M
|
$33.13 M
|
$30.54 M
|
$24.41 M
|
$16.72 M
|
$14.60 M
|
$9.79 M
|
$8.63 M
|
$5.67 M
|
| Other Expenses |
$0.00
|
-$5.07 M
|
-$48.93 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.93 M
|
| Operating Expenses |
$17.46 M
|
$34.79 M
|
$36.65 M
|
$116.18 M
|
$93.81 M
|
$50.78 M
|
$46.90 M
|
$26.83 M
|
$15.87 M
|
$21.00 M
|
| Cost And Expenses |
$0.00
|
$50.76 M
|
$85.58 M
|
$116.18 M
|
$95.22 M
|
$53.45 M
|
$51.16 M
|
$30.21 M
|
$20.87 M
|
$21.00 M
|
| Interest Income |
$0.00
|
$3.28 M
|
$3.35 M
|
$284.00 K
|
$510.00 K
|
$1.40 M
|
$1.80 M
|
$591.00 K
|
$287.00 K
|
$143.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.37 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$383.00 K
|
$386.00 K
|
$326.00 K
|
$285.00 K
|
$109.00 K
|
$80.00 K
|
$53.00 K
|
$85.00 K
|
$58.00 K
|
| EBITDA |
-$17.46 M |
$26.38 M |
-$32.78 M |
-$75.16 M |
-$60.14 M |
-$25.59 M |
-$46.17 M |
-$28.53 M |
$2.47 M |
-$20.95 M |
| EBITDA Ratio |
0
|
0.4
|
-0.67
|
-1.85
|
-2.36
|
-0.88
|
-9.39
|
-17.59
|
0.11
|
0
|
| Operating Income Ratio |
0
|
0.22
|
-0.75
|
-1.85
|
-2.37
|
-0.85
|
-9.41
|
-17.62
|
0.1
|
0
|
| Total Other Income/Expenses Net |
$1.51 M
|
$3.24 M
|
$4.93 M
|
$21.03 M
|
$19.12 M
|
-$22.63 M
|
$29.43 M
|
-$11.48 M
|
$287.00 K
|
$143.00 K
|
| Income Before Tax |
-$15.95 M
|
$17.78 M
|
-$31.84 M
|
-$54.45 M
|
-$41.31 M
|
-$47.17 M
|
-$16.82 M
|
-$40.07 M
|
$2.67 M
|
-$20.86 M
|
| Income Before Tax Ratio |
0
|
0.27
|
-0.65
|
-1.34
|
-1.62
|
-1.63
|
-3.42
|
-24.7
|
0.11
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
| Net Income |
-$15.95 M
|
$17.78 M
|
-$31.84 M
|
-$54.45 M
|
-$41.31 M
|
-$47.17 M
|
-$16.82 M
|
-$40.07 M
|
$2.67 M
|
-$20.86 M
|
| Net Income Ratio |
0
|
0.27
|
-0.65
|
-1.34
|
-1.62
|
-1.63
|
-3.42
|
-24.7
|
0.11
|
0
|
| EPS |
-2.39 |
2.67 |
-4.78 |
-8.75 |
-7.34 |
-10.4 |
-4.73 |
-19.34 |
1.4 |
-12.2 |
| EPS Diluted |
-2.39 |
2.67 |
-4.78 |
-9.99 |
-12 |
-10.4 |
-4.65 |
-19.34 |
1.45 |
-12.13 |
| Weighted Average Shares Out |
$6.66 M
|
$6.66 M
|
$6.66 M
|
$6.22 M
|
$5.63 M
|
$4.55 M
|
$3.56 M
|
$2.07 M
|
$1.85 M
|
$1.71 M
|
| Weighted Average Shares Out Diluted |
$6.66 M
|
$6.66 M
|
$6.66 M
|
$6.26 M
|
$5.72 M
|
$4.55 M
|
$3.62 M
|
$2.07 M
|
$1.91 M
|
$1.72 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
